PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Does the body's immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

2014-01-08
(Press-News.org) Contact information: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Does the body's immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

New Rochelle, NY, January 7, 2014—Packaging replacement genes in viruses is an effective method to deliver them to target tissues, but the human body mounts an immune response against the virus. The systemic and local immune reactions induced by an adeno-associated virus (AAV)-based gene therapy to treat lipoprotein lipase deficiency, approved for use in Europe, does not affect the safety of gene therapy or expression of the replacement gene for at least one year after delivery, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Human Gene Therapy website.

Valeria Ferreira and coauthors, uniQure BV and Academic Medical Center, Amsterdam, the Netherlands, and University of Montreal and Chicoutimi Hospital, Quebec, Canada, evaluated measures of inflammation and adverse clinical events and the expression of a replacement lipoprotein lipase (LPL) gene that was injected intramuscularly into patients with LPL deficiency. The gene was packaged in an AAV vector, as described in the article "Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of Lipoprotein Lipase deficiency (LPLD) gene therapy."

"The clinical data published in this paper were critical to the approval of Glybera," says James Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. "Furthermore, they provide context for laboratory measurements of immune responses which apparently did not impact product performance."



INFORMATION:

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals are Human Gene Therapy Methods, published bimonthly and focused on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly and featuring data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: (914) 740-2100
(800) M-LIEBERT
Fax: (914) 740-2101



ELSE PRESS RELEASES FROM THIS DATE:

Research reveals new therapeutic target for Huntington's disease

2014-01-08
Research reveals new therapeutic target for Huntington's disease

Geography has impact on grapevine moth's success in French vineyards

2014-01-08
Geography has impact on grapevine moth's success in French vineyards Study sheds light on how regional differences, local temperatures influence immune function of pests 'Location, location, location' is an adage also true for the European grapevine moth, it seems. Research ...

Laundering money -- literally -- could save billions of dollars

2014-01-08
Laundering money -- literally -- could save billions of dollars A dollar bill gets around, passing from hand to hand, falling on streets and sidewalks, eventually getting so grimy that a bank machine flags it and sends it to the shredder. Rather than destroying ...

Newly discovered celestial object defies categories

2014-01-08
Newly discovered celestial object defies categories Scientists asking if it is a new kind of planet or a rare kind of failed star TORONTO, ON – An object discovered by astrophysicists at the University of Toronto (U of T) nearly 500 light years away from the Sun ...

Metal ink could ease the way toward flexible electronic books, displays

2014-01-08
Metal ink could ease the way toward flexible electronic books, displays Scientists are reporting the development of a novel metal ink made of small sheets of copper that can be used to write a functioning, flexible electric circuit on regular printer paper. ...

Green space can make people happier for years

2014-01-08
Green space can make people happier for years Nearly 10 years after the term "nature deficit disorder" entered the nation's vocabulary, research is showing for the first time that green space does appear to improve mental health in a sustained way. The report, ...

Top chemical advances and more from the year 2013

2014-01-08
Top chemical advances and more from the year 2013 From stretchy electronics to Martian chemistry, the most notable advances in the chemical world in 2013 appear in the year-in-review issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the ...

AML score that combines genetic and epigenetic changes might help guide therapy

2014-01-08
AML score that combines genetic and epigenetic changes might help guide therapy COLUMBUS, Ohio – Currently, doctors use chromosome markers and gene mutations to determine the best treatment for patients with acute myeloid leukemia (AML). ...

Cosmetic outcomes after breast-conserving therapy may vary by race

2014-01-08
Cosmetic outcomes after breast-conserving therapy may vary by race Subjective ratings appear lower in African-American patients, reports PRS Global Open Philadelphia, Pa. (January 7, 2013) – As perceived by both patients and doctors, the cosmetic results ...

Stopping tumors in their path

2014-01-08
Stopping tumors in their path New study sheds light on most common and deadly form of brain cancer Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumours and occurring mostly in adults between ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] Does the body's immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?